Taking Ozempic? Magic mushrooms may take hours to kick in, or barely work at all
A strange pattern keeps surfacing in our corner of medicine. People on GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) report that psilocybin mushrooms hit late, hit weak, or seem not to hit at all. The mushrooms sit in the stomach for hours, the person assumes nothing is going to happen, and then the effects arrive all at once, sometimes in the back of a taxi on the way home.
We prescribe GLP-1 medications every day, so when patients started asking us about this, we went looking for evidence rather than anecdotes. There is more of it than you might expect: a peer-reviewed social listening study, a formal safety framework from New Mexico's medical psilocybin program, and a clear pharmacological reason the effect happens. Here is what the science actually says.
The short answer
GLP-1 medications slow stomach emptying, and psilocybin needs fast passage through the gut to convert into its active form. The result is a delayed, often weaker, and less predictable experience. The biggest risk is not a bad trip. It is a second dose taken before the first one has landed.
What people are reporting
The most systematic look so far is a 2024 mixed-methods study published in Brain Sciences, which analyzed 5,859 Reddit threads and comments about GLP-1 medications posted between December 2019 and June 2023. Among the substance-related reports, some users described slightly enhanced or extended effects of MDMA with a delayed onset, and the authors noted similar findings for psychedelic mushrooms and ketamine, attributed to GLP-1-associated delayed gastric emptying (1).
Practitioners who work with psilocybin in retreat settings describe the same pattern. Right To Heal, a retreat provider that employs physicians and accepts clients on prescription medications, has written about clients on GLP-1 agonists experiencing very long onset times with muted effects, including one client on Ozempic who felt nothing four hours after dosing, called a taxi home, and began tripping during the ride (2). Psychedelics Today summarized the emerging reports as onset delayed beyond two hours, blunted or unpredictable effects, abrupt drop-offs instead of a gradual taper, and "non-event" sessions where no noticeable effects occur at all (3).
Why it happens: the stomach, not the mushrooms
This is not the mushrooms being weak, and it is not in anyone's head. It is pharmacology.
GLP-1 medications slow gastric emptying. That effect is part of how they work: food leaves the stomach more slowly, blood sugar rises more gently, and appetite stays quieter. The Ozempic label itself describes a delay in gastric emptying in the early post-meal period, and the current label also carries a warning about residual stomach contents and rare cases of pulmonary aspiration during anesthesia, added after postmarketing reports (4). A 2024 review in The Journal of Clinical Endocrinology & Metabolism walks through what that retained gastric content means clinically, from unexpected findings at endoscopy to airway complications under sedation (5).
Psilocybin, meanwhile, is a prodrug. The mushroom material has to break down in the gut, and the psilocybin has to be converted into psilocin, the compound that actually crosses into the brain. Much of that conversion happens in the small intestine, driven by alkaline phosphatase enzymes. Even in people with normal digestion, a 2025 systematic review in Pharmaceutics puts the time to peak psilocin levels at 1.8 to 4 hours after oral psilocybin (8).
Now put the two together. A 2025 modeling study in Pharmacotherapy, built on capsule endoscopy data from patients taking liraglutide, estimated that GLP-1 treatment extends gastric residence from about 1 hour to about 4 hours and stretches mean small intestine transit from 3.3 hours to 9 hours (6). The model then predicted the knock-on effect on other oral drugs: delayed gastric emptying raised overall exposure by 64% for rosuvastatin, 90% for valsartan, and 205% for the anticoagulant dabigatran. Slower emptying does not just make absorption later. It can make it larger, messier, and harder to predict.
Whole mushrooms add a second problem. Psilocybin is locked inside fungal cell walls made of chitin, which the stomach has to grind and soak in acid before it can release the drug. A slow stomach means that breakdown takes longer too. And because absorption is smeared out instead of arriving in a single wave, the peak concentration of psilocin can end up lower, which is a plausible reason experiences feel muted rather than merely late. A systematic review of GLP-1 drug interactions in Drug Safety found exactly this signature across many oral medications: unchanged or reduced peak levels with delayed time to peak (7).
Could GLP-1s be changing the experience itself?
Possibly, though the evidence here is much earlier. GLP-1 receptors are not just in the gut. They also sit in brain regions involved in reward, including the ventral tegmental area and the nucleus accumbens. In rodents, semaglutide reduced alcohol intake and relapse-like drinking (11), and both semaglutide and tirzepatide blunted cocaine-evoked dopamine surges in the nucleus accumbens while reducing drug taking, motivation, and seeking (12, 13).
Psychedelics work mainly through serotonin 5-HT2A receptors rather than dopamine reward, so those findings do not map cleanly onto psilocybin. Still, the euphoria, intensity, and sense of significance in a psychedelic experience likely lean on reward circuits to some degree. Whether GLP-1 medications genuinely blunt the subjective effects of psilocybin, or simply delay its delivery, is not known yet. The gut explanation is the one with solid evidence behind it today.
The real risk: taking more
Here is the part that has regulators paying attention. In early 2026, New Mexico's Medical Psilocybin Advisory Board placed GLP-1 medications such as semaglutide and tirzepatide in Tier 2 of its patient qualification and safety framework, the level that calls for enhanced clinical support and a documented risk mitigation plan. The framework applies to GLP-1 use within two weeks of a psilocybin session, and the committee's medication interaction table states the concern plainly: "Potential to significantly delay onset. If additional dosing is provided due to delay the potential for over dosing is substantial" (10).
Walk through the mechanics. Someone takes a dose, feels nothing at 90 minutes, and takes more. Meanwhile the first dose is still sitting in the stomach. When gastric emptying finally catches up two or three hours later, both doses reach the small intestine around the same time. What arrives is not a slightly stronger version of the experience that was planned. It is a much larger one, landing when nobody expects it.
What practitioners are changing
This is an area where practice is moving faster than research, so it is worth describing what the field is doing without endorsing any of it. Psilocybin remains a Schedule I substance under federal law, and none of this is a recommendation to use it.
Retreat clinicians report asking clients to disclose GLP-1 use, the dose, and how recently it was escalated, then planning for a much longer onset window and counseling explicitly against redosing (2, 3). Some providers have shifted to pre-converted preparations such as lemon tek, where ground mushrooms soak in an acidic liquid before ingestion, on the theory that this does the conversion work the slow stomach would otherwise be responsible for. Others are watching the development of sublingual psilocin formulations, which would bypass the gut entirely by absorbing through the mouth, with reported onset around 10 to 20 minutes and no first-pass liver metabolism (3). Most of those products are still in development and not widely available.
What we still don't know
No controlled study has ever co-administered a GLP-1 medication and psilocybin. The absolute bioavailability of psilocin rests largely on a single historical estimate of about 55%, and food effects on psilocybin absorption have not been systematically studied (9). Most GLP-1 interaction studies enrolled healthy volunteers, so the picture in people with obesity, diabetes, or existing gut motility problems is thinner (7). There is also an open question in the other direction: early animal research suggests low, non-psychedelic doses of psilocybin may influence metabolic health through 5-HT2B receptor pathways in the liver (14). Whether GLP-1s and psilocybin complement or collide on metabolic ground is unstudied.
What this means if you take a GLP-1
If you use psilocybin in any setting, the practical takeaway is about predictability rather than potency. GLP-1 use changes how the drug reaches you: onset can be hours late, effects can feel weaker, and the timing is less reliable than it is for most people. The one hard rule is to never redose because nothing has happened yet. And any clinician involved in your care, including your GLP-1 prescriber, deserves to know about anything else you take, since the medication changes how so many things are absorbed. We have written before about semaglutide and substance use, and about what GLP-1s do to the gut in our GLP-1 and IBS piece. If you are curious about the broader picture, our review of the off-label benefits of GLP-1 medications covers where the evidence stands.
If you have questions about your GLP-1 medication, its side effects, or how it interacts with anything else in your life, book a consultation at Better Off and let's talk about your goals.
References:
- Arillotta D, et al. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sciences, 2024.
- Right To Heal. Ozempic & Mushrooms. July 2024.
- Moore J. GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin. Psychedelics Today, August 2025.
- Ozempic (semaglutide) Prescribing Information. FDA-approved labeling: Clinical Pharmacology 12.2 and Warning 5.9, Pulmonary Aspiration During General Anesthesia or Deep Sedation.
- Jalleh RJ, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of Clinical Endocrinology & Metabolism, 2024.
- Hooper L, et al. GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy, 2025.
- Calvarysky B, et al. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Safety, 2024.
- Meshkat S, et al. Pharmacokinetics of Psilocybin: A Systematic Review. Pharmaceutics, 2025.
- Otto ME, et al. Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis. Clinical Pharmacokinetics, 2025.
- New Mexico Department of Health, Medical Psilocybin Advisory Board, Patient Qualification & Safety Committee. Medication Interactions framework, 2026.
- Aranäs C, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine, 2023.
- Aranäs C, et al. Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens. European Neuropsychopharmacology, 2025.
- Edvardsson CE, et al. Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents. EBioMedicine, 2026.
- Colognesi M, et al. Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms. Pharmacological Research, 2026.
Disclaimer: This article is for informational purposes only and is not medical advice. Psilocybin is a Schedule I controlled substance under federal law and is not approved to treat any condition; we do not recommend using it. GLP-1 medications are prescription drugs. Always talk to your own provider about your medications and any substance use.